203 related articles for article (PubMed ID: 25604729)
1. Intensity-modulated proton therapy for elective nodal irradiation and involved-field radiation in the definitive treatment of locally advanced non-small-cell lung cancer: a dosimetric study.
Kesarwala AH; Ko CJ; Ning H; Xanthopoulos E; Haglund KE; O'Meara WP; Simone CB; Rengan R
Clin Lung Cancer; 2015 May; 16(3):237-44. PubMed ID: 25604729
[TBL] [Abstract][Full Text] [Related]
2. Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): A comparative analysis of toxicities and clinical outcomes.
Fernandes AT; Shen J; Finlay J; Mitra N; Evans T; Stevenson J; Langer C; Lin L; Hahn S; Glatstein E; Rengan R
Radiother Oncol; 2010 May; 95(2):178-84. PubMed ID: 20356642
[TBL] [Abstract][Full Text] [Related]
3. Dose escalation of chart in non-small cell lung cancer: is three-dimensional conformal radiation therapy really necessary?
McGibney C; Holmberg O; McClean B; Williams C; McCrea P; Sutton P; Armstrong J
Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):339-50. PubMed ID: 10487554
[TBL] [Abstract][Full Text] [Related]
4. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation.
Grills IS; Yan D; Martinez AA; Vicini FA; Wong JW; Kestin LL
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):875-90. PubMed ID: 14529795
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Toxicity Between Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy for Locally Advanced Non-small-cell Lung Cancer.
Ling DC; Hess CB; Chen AM; Daly ME
Clin Lung Cancer; 2016 Jan; 17(1):18-23. PubMed ID: 26303127
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study.
Jeter MD; Gomez D; Nguyen QN; Komaki R; Zhang X; Zhu X; O'Reilly M; Fossella FV; Xu T; Wei X; Wang H; Yang W; Tsao A; Mohan R; Liao Z
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):730-737. PubMed ID: 29248169
[TBL] [Abstract][Full Text] [Related]
7. IMRT and 3D conformal radiotherapy with or without elective nodal irradiation in locally advanced NSCLC: A direct comparison of PET-based treatment planning.
Fleckenstein J; Kremp K; Kremp S; Palm J; Rübe C
Strahlenther Onkol; 2016 Feb; 192(2):75-82. PubMed ID: 26438071
[TBL] [Abstract][Full Text] [Related]
8. Small-spot intensity-modulated proton therapy and volumetric-modulated arc therapies for patients with locally advanced non-small-cell lung cancer: A dosimetric comparative study.
Liu C; Sio TT; Deng W; Shan J; Daniels TB; Rule WG; Lara PR; Korte SM; Shen J; Ding X; Schild SE; Bues M; Liu W
J Appl Clin Med Phys; 2018 Nov; 19(6):140-148. PubMed ID: 30328674
[TBL] [Abstract][Full Text] [Related]
9. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study.
Zhang X; Li Y; Pan X; Xiaoqiang L; Mohan R; Komaki R; Cox JD; Chang JY
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):357-66. PubMed ID: 19660879
[TBL] [Abstract][Full Text] [Related]
10. Improve dosimetric outcome in stage III non-small-cell lung cancer treatment using spot-scanning proton arc (SPArc) therapy.
Li X; Kabolizadeh P; Yan D; Qin A; Zhou J; Hong Y; Guerrero T; Grills I; Stevens C; Ding X
Radiat Oncol; 2018 Feb; 13(1):35. PubMed ID: 29486782
[TBL] [Abstract][Full Text] [Related]
11. Involved-field radiotherapy (IFRT) versus elective nodal irradiation (ENI) in combination with concurrent chemotherapy for 239 esophageal cancers: a single institutional retrospective study.
Yamashita H; Takenaka R; Omori M; Imae T; Okuma K; Ohtomo K; Nakagawa K
Radiat Oncol; 2015 Aug; 10():171. PubMed ID: 26269033
[TBL] [Abstract][Full Text] [Related]
12. An in-silico comparison of proton beam and IMRT for postoperative radiotherapy in completely resected stage IIIA non-small cell lung cancer.
Berman AT; Teo BK; Dolney D; Swisher-McClure S; Shahnazi K; Both S; Rengan R
Radiat Oncol; 2013 Jun; 8():144. PubMed ID: 23767810
[TBL] [Abstract][Full Text] [Related]
13. Proton arc reduces range uncertainty effects and improves conformality compared with photon volumetric modulated arc therapy in stereotactic body radiation therapy for non-small cell lung cancer.
Seco J; Gu G; Marcelos T; Kooy H; Willers H
Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):188-94. PubMed ID: 23920395
[TBL] [Abstract][Full Text] [Related]
14. Analysis of incidental radiation dose to uninvolved mediastinal/supraclavicular lymph nodes in patients with limited-stage small cell lung cancer treated without elective nodal irradiation.
Ahmed I; DeMarco M; Stevens CW; Fulp WJ; Dilling TJ
Med Dosim; 2011; 36(4):440-7. PubMed ID: 21397488
[TBL] [Abstract][Full Text] [Related]
15. Dosimetric feasibility of 4DCT-ventilation imaging guided proton therapy for locally advanced non-small-cell lung cancer.
Huang Q; Jabbour SK; Xiao Z; Yue N; Wang X; Cao H; Kuang Y; Zhang Y; Nie K
Radiat Oncol; 2018 Apr; 13(1):78. PubMed ID: 29695284
[TBL] [Abstract][Full Text] [Related]
16. Results of a preliminary study using hypofractionated involved-field radiation therapy and concurrent carboplatin/paclitaxel in the treatment of locally advanced non-small-cell lung cancer.
Matsuura K; Kimura T; Kashiwado K; Fujita K; Akagi Y; Yuki S; Murakami Y; Wadasaki K; Monzen Y; Ito A; Kagemoto M; Mori M; Ito K; Nagata Y
Int J Clin Oncol; 2009 Oct; 14(5):408-15. PubMed ID: 19856048
[TBL] [Abstract][Full Text] [Related]
17. Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer.
Register SP; Zhang X; Mohan R; Chang JY
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1015-22. PubMed ID: 20615629
[TBL] [Abstract][Full Text] [Related]
18. Dose distribution and tumor control probability in out-of-field lymph node stations in intensity modulated radiotherapy (IMRT) vs 3D-conformal radiotherapy (3D-CRT) of non-small-cell lung cancer: an in silico analysis.
Fleckenstein J; Eschler A; Kremp K; Kremp S; Rübe C
Radiat Oncol; 2015 Aug; 10():178. PubMed ID: 26292716
[TBL] [Abstract][Full Text] [Related]
19. Risk of isolated nodal failure for non-small cell lung cancer (NSCLC) treated with the elective nodal irradiation (ENI) using 3D-conformal radiotherapy (3D-CRT) techniques--a retrospective analysis.
Kepka L; Bujko K; Zolciak-Siwinska A
Acta Oncol; 2008; 47(1):95-103. PubMed ID: 17851862
[TBL] [Abstract][Full Text] [Related]
20. Limited Impact of Setup and Range Uncertainties, Breathing Motion, and Interplay Effects in Robustly Optimized Intensity Modulated Proton Therapy for Stage III Non-small Cell Lung Cancer.
Inoue T; Widder J; van Dijk LV; Takegawa H; Koizumi M; Takashina M; Usui K; Kurokawa C; Sugimoto S; Saito AI; Sasai K; Van't Veld AA; Langendijk JA; Korevaar EW
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):661-9. PubMed ID: 27681763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
